Core Viewpoint - The Gross Law Firm is notifying shareholders of Viatris Inc. regarding a class action lawsuit related to misleading statements about the company's Indore, India facility inspection and its subsequent financial performance [1][3]. Group 1: Allegations and Financial Impact - The class period for the lawsuit is from August 8, 2024, to February 26, 2025 [3]. - The complaint alleges that Viatris misrepresented the significance of a warning letter from the FDA regarding its Indore facility, downplaying it as a "minor headwind" [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris attributed its below-expectation guidance to the financial impact from the Indore facility warning letter and import alert [3]. - On February 27, 2025, Viatris' stock price fell from $11.24 to $9.53, a decline of approximately 15.21% in one day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. ...

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=146170&from=4CLASS PERIOD: August 8, 2024 to February 2 ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/viatris-inc-lawsuit-submissio ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company t ...

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud that negatively impacted investors between August 8, 2024, and February 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying it as a "minor headwind" [2]. - Following the announcement of disappointing financial results for Q4 and fiscal year 2024, Viatris' stock price dropped from $11.24 to $9.53 per share, a decline of approximately 15.21% in one day [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=145083&from=3 CLASS PERIOD: August 8, 2024 to ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Viatris Inc. regarding a class action lawsuit related to misleading statements about the company's Indore, India facility inspection and its subsequent financial performance [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Viatris' management misrepresented the significance of a warning letter from the FDA concerning the Indore facility, downplaying it as a "minor headwind" [1]. - Following the announcement of disappointing financial results for Q4 and fiscal year 2024, Viatris attributed its below-expectation guidance to the financial impact of the warning letter and import alert [1]. Financial Impact - On February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53 per share, marking a decline of approximately 15.21% in one day [1]. Class Action Details - Shareholders who purchased shares during the class period from August 8, 2024, to February 26, 2025, are encouraged to register for the class action, with a deadline of June 3, 2025, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the upcoming lead plaintiff deadline on June 3, 2025, for a class action lawsuit related to misleading statements about the company's Indore, India facility inspection [1][4]. Group 1: Class Action Details - Investors who purchased Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [2]. - The lawsuit alleges that Viatris provided misleading information regarding the FDA's warning letter and import alert affecting eleven products from its Indore facility, which were downplayed as a "minor headwind" [4][5]. Group 2: Misleading Statements and Financial Impact - Defendants allegedly failed to disclose critical information about the timing of the inspection, the duration of remediation efforts, and the financial implications of these actions [5]. - The lawsuit claims that the misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true details became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company [3].